^
10h
New P1 trial • Combination therapy
|
Rituxan (rituximab) • CD19.t-haNK
10h
Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization. (PubMed, J Clin Exp Hematop)
The 5 cases shared IGHV preferentially used in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in the latter may be different from that of the former.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL3 (BCL3 Transcription Coactivator)
|
MYC expression
11h
Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion. (PubMed, J Biol Chem)
In clinical lymphoma samples, the expression of METTL3, YTHDF1 and TLR9 was highly correlated with immune cells infiltration. This study reveals a novel mechanism that EBV represses the important innate immunity molecule TLR9 through modulating the host m6A modification system.
Journal • IO biomarker
|
TLR9 (Toll Like Receptor 9) • METTL3 (Methyltransferase Like 3) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
TLR9 expression
14h
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. (PubMed, Blood Adv)
In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), R-CHOP (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21). Grade 3-4 neutropenia and thrombocytopenia events were most frequent with intensive chemoimmunotherapy + venetoclax; grade 3-4 infection rates were similar across treatment groups. In this difficult-to-treat RT patient population, venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in a subset of patients.
Clinical • Journal • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • Rituxan (rituximab)
14h
Recent advances in understanding the biology of follicular lymphoma. (PubMed, Int J Hematol)
Recent evidence suggests that this chronic BCR signaling drives FL polarization toward a dark-zone phenotype and promotes clonal evolution. Since both epigenetic and post-transcriptional modifications of B cells have been implicated in the early stage of FL development, it may be possible to use novel non-chemotherapeutic approaches that interfere with the immunobiology in treatment or early prevention of FL.
Review • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 overexpression
15h
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia. (PubMed, Curr Hematol Malig Rep)
The findings of the RAINBOW trial (NCT046152), comparing the dexamethasone, rituximab, and cyclophosphamide (DRC) regimen to the first-generation, ibrutinib are awaited, but more studies are needed to draw definitive conclusions on the comparative efficacy of chemoimmunotherapy and BTKi. Complete response is elusive with BTKi, and combination regimens to improve upon the efficacy and limit the treatment duration are also under evaluation in WM.
Review • Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
|
MYD88 mutation • MYD88 L265P • BTK C481 • MYD88 wild-type
|
Imbruvica (ibrutinib) • Rituxan (rituximab) • cyclophosphamide
17h
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients-Case Control Study. (PubMed, Med Sci (Basel))
Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.
Journal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*11
18h
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. (PubMed, J Immunother Cancer)
This biomarker analysis expands on clinical findings of odronextamab in patients with R/R B-NHL, providing verification of the suitability of CD20 as a therapeutic target, as well as evidence for potential mechanisms of action and resistance.
Journal • Immune cell
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD79B (CD79b Molecule) • CD22 (CD22 Molecule)
|
CD20 expression
|
odronextamab (REGN1979)
18h
Nodal Low-Grade B-Cell Lymphoma Co-Expressing CD5 and CD10 but Not CD23, IRTA1, or Cyclin D1: The Diagnostic Challenge of a Splenic Marginal Zone Lymphoma. (PubMed, Diagnostics (Basel))
The dual expression of CD5 and CD10 is extremely unusual for low-grade BCL and may lead to an erroneous diagnosis. Integrating the findings into peripheral blood smear tests, flow cytometry, histopathology, imaging, and clinical features is mandatory to exclude other lymphoma types and to reach a correct diagnosis, particularly for a case with nodal presentation.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • FCER2 (Fc Fragment Of IgE Receptor II)
|
CCND1 expression
18h
Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview. (PubMed, Hematol Rep)
Treatment approaches are evolving, with chemoimmunotherapy remaining standard for many indolent cases while intensified regimens and targeted agents show promise for refractory or high-risk aggressive disease. Continued elucidation of the genetic and microenvironmental underpinnings of lymphomagenesis is critical for developing personalized therapeutic strategies.
Review • Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC translocation
19h
Modulating Cholesterol Metabolism via ACAT1 Knockdown Enhances Anti-B-Cell Lymphoma Activities of CD19-Specific Chimeric Antigen Receptor T Cells by Improving the Cell Activation and Proliferation. (PubMed, Cells)
Moreover, the knockdown of ACAT1 led to better anti-tumor efficacy of anti-CD19 CAR-T cells in the B-cell lymphoma mice model. Our study demonstrates novel CAR-T cells containing ACAT1 shRNA with improved efficacy compared to conventional anti-CD19-CAR-T cells in vitro and in vivo.
Journal • CAR T-Cell Therapy
|
IFNG (Interferon, gamma) • CD69 (CD69 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • ACAT1 (Acetyl-CoA Acetyltransferase 1)
|
CD19 expression • IFNG expression
22h
Neuro-protective Effect of Acetyl-11-keto-β-boswellic Acid in a Rat Model of Scopolamine-induced Cholinergic Dysfunction. (PubMed, Curr Pharm Des)
The results suggested the effectiveness of AKBA in preventing learning and memory dysfunction induced by scopolamine. Accordingly, these protective effects might be produced by modulating BDNF, cholinergic system function, oxidative stress, and apoptotic markers.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BDNF (Brain Derived Neurotrophic Factor)
|
BCL2 expression
1d
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL (clinicaltrials.gov)
P3, N=475, Active, not recruiting, Fujian Medical University | Recruiting --> Active, not recruiting
Enrollment closed
1d
New P2 trial
|
Gazyva (obinutuzumab) • Jaypirca (pirtobrutinib)
1d
Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma. (PubMed, Discov Med)
In summary, FLOT2 functions as an oncogene and is linked to DLBCL prognosis and the tumor microenvironment. Targeting FLOT2 deletion emerges as a novel strategy to impede DLBCL aggressiveness by inhibiting cell proliferation and invasion, ultimately inducing apoptotic cell death.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • SIGLEC15 (Sialic Acid Binding Ig Like Lectin 15)
1d
Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma. (PubMed, Sci Rep)
Here, we set out to identify an epigenetic regulator drug that acts synergistically with doxorubicin in EBV-positive lymphoma...We further observed that SOX2 expression was altered in response to CHAC2 expression, suggesting that stemness is regulated. Collectively, these findings suggest that LSD1 inhibitors could serve as promising therapeutic candidates for EBV-positive lymphoma, potentially reducing stemness activity when combined with conventional drugs to offer an effective treatment approach.
Journal
|
SOX2
|
SOX2 expression
|
doxorubicin hydrochloride
2d
Differential carbonic anhydrase activities control EBV-induced B-cell transformation and lytic cycle reactivation. (PubMed, PLoS Pathog)
In contrast, during lytic cycle reactivation CA9 expression is transcriptionally suppressed by the key EBV lytic cycle transactivator, BZLF1 through its transactivation domain. Overall, our study highlights the dynamic alterations of CA9 expression and its activity in regulating pH homeostasis act as one of the major drivers for EBV induced B-cell transformation and subsequent B-cell lymphomagenesis.
Journal
|
CA9 (Carbonic anhydrase 9)
|
CA9 expression
2d
Role of Rad18 in B cell activation and lymphomagenesis. (PubMed, Sci Rep)
Also, tumour subtypes do not differ between the mouse models. Accordingly, functions of Rad18 in B cell activation and tumorigenesis may be compensated for by other pathways in B cells.
Journal
|
PCNA (Proliferating cell nuclear antigen)
2d
New trial
|
imvotamab (IGM-2323)
2d
EPCORE NHL-1: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (clinicaltrials.gov)
P1/2, N=666, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | Trial completion date: Apr 2029 --> Jan 2029
Enrollment closed • Trial completion date
|
CD20 positive
|
Epkinly (epcoritamab-bysp)
2d
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=130, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement
|
Venclexta (venetoclax) • enitociclib (VIP152)
2d
Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL (clinicaltrials.gov)
P=N/A, N=400, Recruiting, AstraZeneca | Trial completion date: Dec 2024 --> May 2024 | Trial primary completion date: Oct 2024 --> May 2024
Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world
2d
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=13, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
Trial completion
|
Blincyto (blinatumomab)
2d
Enrollment open • Combination therapy
2d
BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
P1/2, N=860, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Apr 2024 --> Jan 2028 | Trial primary completion date: Apr 2024 --> Sep 2027
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
3d
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. (PubMed, Cell Rep Med)
The core autoregulatory transcriptional circuitry activity is reinforced by MYC binding to the enhancer regions associated with STAT3 and each of the core regulatory transcription factors. Thus, activation of STAT3 provides the crucial link between aberrant tyrosine kinase signaling and the core transcriptional machinery that drives tumorigenesis and creates therapeutic vulnerabilities in ALCL.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IKZF1 (IKAROS Family Zinc Finger 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • IRF4 (Interferon regulatory factor 4) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
|
ALK fusion • ALK mutation
3d
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=40, Recruiting, Novartis Pharmaceuticals | N=124 --> 40 | Trial completion date: Jun 2027 --> Oct 2026 | Trial primary completion date: Jun 2027 --> Oct 2026
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
lenalidomide • ianalumab (VAY736)
4d
Clinicopathological features of adult T-cell leukemia/lymphoma with T-follicular helper phenotype. (PubMed, Cancer Med)
Some patients with ATLL may present a TFHP, which should not preclude the diagnosis of ATLL. Although presenting a TFHP does not affect prognosis, it is important to identify cases of ATLL with a TFHP since it may inform future treatment strategies.
Journal
|
FOXP3 (Forkhead Box P3) • CRP (C-reactive protein)
|
FOXP3 expression
4d
Characterization of primary small intestinal lymphoma: a retrospective study based on double balloon endoscopy. (PubMed, BMC Gastroenterol)
This study provides clinical characteristics of patients with PSIL. Thicker intestinal wall and aneurismal dilation detected on CT scan and deeper ulcer on DBE examination helps to establish a diagnosis of DLBCL.
Retrospective data • Journal
|
CRP (C-reactive protein)
|
LDH elevation
4d
High-grade B-cell lymphoma with a quadruple-hit genetic profile including concurrent MYC, BCL2, BCL6, and CCND1 gene rearrangements. (PubMed, Lab Med)
Case 1 represented a 59-year-old female with widespread lymphadenopathy and a diagnosis of HGBL who exhibited primary refractoriness to dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) chemotherapy...Similarly, a literature review of 7 previously reported cases of HGBL with a quadruple-hit profile also demonstrated aggressive disease behavior. Our study adds 2 new cases to the rarely encountered quadruple-hit HGBL, and a brief meta-analysis of the 9 available cases indicates aggressive disease behavior conferred by this constellation of genetic events.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Epoch (epoetin beta biosimilar)
4d
Vulnerability to APOBEC3G linked to the pathogenicity of deltaretroviruses. (PubMed, Proc Natl Acad Sci U S A)
Thus, HTLV-1 is vulnerable to hA3G but utilizes it to promote the proliferation of infected cells via the activation of the TGF-β/Smad pathway. Antisense factors in each virus, differently adapted to control host cellular functions through A3G, seem to dictate the pathogenesis.
Journal
|
IRF4 (Interferon regulatory factor 4) • TGFB1 (Transforming Growth Factor Beta 1) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
4d
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations. (PubMed, J Neurol Sci)
The patient's diagnosis highlights the importance of considering diseases previously confined to specific endemic regions in a globalized world where increased emigration and population mixing can occur. Early identification and management of such cases is essential for optimizing patient outcomes and quality of life.
Review • Journal
|
CD4 (CD4 Molecule)
5d
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression. (PubMed, Cancer Genet)
The findings suggest more frequent alterations of 11q in diffuse large B cell lymphoma (DLBCL)/HGBCL-GC BCL2-, in comparison to cases of Burkitt lymphoma (BL) or DLBCL-GC BCL2+, and confirm a low genomic complexity score of BL. Variability identified in patterns of 11q alterations suggests genomic array studies may afford value over FISH testing as we continue to understand HGBCL-11q as a distinct entity, and interrogate cases of DLBCL/HGBCL-GC BCL2-.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
5d
In silico design of potential Mcl-1 peptide-based inhibitors. (PubMed, J Mol Model)
Finally, molecular dynamics simulations run for 100 ns were done using the GROMACS, version 5.0.7, with the CHARMM36 force field. MM-PBSA was used to assess binding affinity specificity in targeting Mcl-1 and Bcl-xL (B-cell lymphoma extra-large).
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
MCL1 overexpression • MCL1 expression
6d
Biomarkers and coptis chinensis activity for rituximab-resistant diffuse large B-cell lymphoma: Combination of bioinformatics analysis, network pharmacology and molecular docking. (PubMed, Technol Health Care)
Berberine, quercetin, epiberberine and palmatine, the active components of Coptis chinensis, have great potential for improving rituximab-resistant DLBCL via PIK3CG. This study revealed biomarkers and Coptis chinensis-associated molecular functions for rituximab-resistant DLBCL.
Journal
|
PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma)
|
Rituxan (rituximab)
6d
Identification of a prognostic signature based on five ferroptosis-related genes for diffuse large B-cell lymphoma. (PubMed, Cancer Biomark)
The newly developed signature involving GOP1, GPX2, SLC7A5, ATF4, and CXCL2 has the potential to serve as a prognostic biomarker. Furthermore, our results provide additional support for the contribution of ferroptosis to DLBCL.
Journal
|
SLC7A5 (Solute Carrier Family 7 Member 5) • ATF4 (Activating Transcription Factor 4) • GPX2 (Glutathione peroxidase 2 (gastrointestinal))
6d
Lactate dehydrogenase A is implicated in the pathogenesis of B-cell lymphoma through regulation of the FER signaling pathway. (PubMed, Biofactors)
Treatment with E260, a FER inhibitor, significantly reduced the metabolism, proliferation and invasion of Raji cells. In summary, our findings highlight that LDHA plays multiple roles in B-cell lymphoma pathogenesis via FER pathways, establishing LDHA/FER may as a potential therapeutic target.
Journal
|
LDHA (Lactate dehydrogenase A)
|
LDH elevation
6d
EXALT-2: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (clinicaltrials.gov)
P=N/A, N=150, Recruiting, Medical University of Vienna | Trial completion date: Dec 2024 --> Mar 2026 | Trial primary completion date: Dec 2024 --> Mar 2026
Trial completion date • Trial primary completion date
|
FoundationOne® Heme CDx
6d
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma (clinicaltrials.gov)
P1, N=10, Terminated, Amgen | Completed --> Terminated; Amgen decided to discontinue study because of a business decision and not because of safety reasons
Trial termination
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
AMG 562
6d
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia (clinicaltrials.gov)
P1, N=60, Completed, Institut de Recherches Internationales Servier | Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023
Trial completion • Trial completion date • Trial primary completion date
|
S65487
6d
NCI-2021-12489: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=42, Recruiting, University of Washington | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
Gazyva (obinutuzumab) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)